Drug Price Trends for NDC 69097-0655

Average Pharmacy Cost for 69097-0655

Drug Name	NDC	Price/Unit ($)	Unit	Date
RITONAVIR 100 MG TABLET	69097-0655-02	0.65211	EACH	2026-03-18
RITONAVIR 100 MG TABLET	69097-0655-02	0.69868	EACH	2026-02-18
RITONAVIR 100 MG TABLET	69097-0655-02	0.76748	EACH	2026-01-21

Best Wholesale Price for NDC 69097-0655

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Eliquis (Apixaban) Market Analysis and Price Projections

Last updated: February 18, 2026

Apixaban, marketed as Eliquis, is a direct oral anticoagulant (DOAC) with a significant and growing market presence. Its efficacy in preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and treating deep vein thrombosis (DVT) and pulmonary embolism (PE) underpins its commercial success. This analysis examines the current market landscape, key drivers, competitive pressures, and future price projections for apixaban.

What is the Current Market Size and Growth Trajectory for Apixaban?

The global apixaban market reached an estimated \$25.6 billion in 2023, driven by increasing diagnoses of cardiovascular diseases, growing awareness of DOAC benefits over traditional anticoagulants like warfarin, and expanding patient populations eligible for treatment [1]. The market is projected to grow at a compound annual growth rate (CAGR) of approximately 8.5% from 2024 to 2030, potentially reaching over \$45 billion by the end of the forecast period [2].

Key Market Drivers:

• Rising Incidence of Atrial Fibrillation: The global prevalence of NVAF is increasing due to aging populations and lifestyle factors, directly expanding the addressable market for apixaban [3].
• Superior Safety and Efficacy Profile: Apixaban demonstrates a lower risk of major bleeding compared to warfarin and other DOACs in certain patient subgroups, alongside comparable or superior efficacy in preventing thromboembolic events [4]. This translates to improved patient outcomes and reduced healthcare costs associated with bleeding complications.
• Convenience of Oral Administration: Unlike warfarin, which requires regular International Normalized Ratio (INR) monitoring, apixaban offers a fixed-dose, once-daily regimen, enhancing patient adherence and reducing the burden on healthcare systems.
• Expanding Clinical Indications and Geographic Reach: Approvals for apixaban in new indications, such as extended duration treatment for DVT and PE, and its growing availability in emerging markets, further fuel market expansion.

Market Segmentation:

• Indication:
  • Non-Valvular Atrial Fibrillation (NVAF) - The largest segment, accounting for an estimated 70% of apixaban's market share.
  • Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) - A significant and growing segment, projected to increase by 15% annually.
• Dosage Form:
  • 2.5 mg tablets
  • 5 mg tablets
• Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

What is the Competitive Landscape for Apixaban?

The DOAC market is highly competitive, with apixaban (Eliquis) facing substantial competition from other major players. Bristol Myers Squibb and Pfizer, the co-developers of Eliquis, maintain a dominant position, but patent expiries and the emergence of generic alternatives are key factors shaping the future competitive environment.

Key Competitors:

• Rivaroxaban (Xarelto): Developed by Bayer AG, rivaroxaban is apixaban's primary competitor. It is approved for similar indications (NVAF, DVT/PE treatment and prevention) and offers a once-daily dosing regimen. Market share for rivaroxaban is estimated at approximately 25% of the DOAC market.
• Edoxaban (Lixiana/Savaysa): Developed by Daiichi Sankyo, edoxaban is another oral anticoagulant with a once-daily dosing. Its market share is smaller, estimated at around 5%, often targeting specific patient profiles or regions where it has secured stronger market access.
• Dabigatran (Pradaxa): Developed by Boehringer Ingelheim, dabigatran was one of the first DOACs to enter the market. It is also a direct thrombin inhibitor and is dosed twice daily. Dabigatran holds an estimated 5% market share.
• Warfarin: While not a DOAC, warfarin remains a significant comparator and a treatment option in certain cost-sensitive markets or for patients with specific contraindications to DOACs.

Patent Landscape and Generic Entry:

The primary patents protecting Eliquis are expiring in key markets.

• United States: Key composition of matter patents expired in 2026. However, secondary patents related to methods of use and formulations have extended exclusivity for some aspects. The first generic versions of apixaban were approved by the FDA in late 2023.
• Europe: Patents in Europe have seen earlier expiry dates, with generic competition emerging in key European Union countries starting from 2022.
• Other Markets: Patent expiries vary significantly by country, with some markets already experiencing generic entry while others are projected to see it in the coming years.

The entry of generics is expected to significantly disrupt pricing dynamics. Studies estimate that generic DOACs can reduce the average wholesale price by 30-50% within two years of their market introduction [5].

What are the Pricing Dynamics and Future Projections for Apixaban?

Apixaban's pricing has historically been high, reflecting its innovation, clinical benefits, and market exclusivity. The average wholesale price (AWP) for a 30-day supply of apixaban (5 mg twice daily) in the U.S. has ranged from \$450 to \$550. This pricing is influenced by payer negotiations, formulary placement, and patient assistance programs.

Current Pricing Trends:

• Brand Name Price Erosion: As patent protections wane and generic competition intensifies, the price of branded Eliquis is expected to decline. However, manufacturers often maintain premium pricing for a period post-generic entry, especially for established brands with strong market recognition and payer loyalty.
• Generic Price Competition: The introduction of multiple generic apixaban products will lead to significant price reductions. Competition among generic manufacturers will drive prices down rapidly, with projections indicating a 40-60% decrease in average selling price within the first 18 months of widespread generic availability.
• Payer Negotiations: Payers (insurance companies and government health programs) play a crucial role in pricing. As generics become available, payers will increasingly favor lower-cost generic options, pressuring branded Eliquis pricing downwards.

Price Projections:

• 2024-2025: Branded Eliquis prices are expected to stabilize or see modest single-digit percentage decreases as generic competition begins to emerge in the US. Generic apixaban will enter the market at a significantly lower price point, estimated to be 30-40% below the branded AWP.
• 2026-2028: Widespread generic availability will lead to substantial price erosion for branded Eliquis. The average selling price for apixaban (both branded and generic) is projected to decrease by 50-70% from its peak 2023 levels. Generic apixaban is expected to capture over 70% of the market volume by 2027.
• Post-2028: Pricing will largely be dictated by generic competition. Prices may continue to decline gradually as manufacturers compete on volume and efficiency. The focus for the original manufacturer will shift to lifecycle management of the brand and potentially developing next-generation anticoagulants.

Factors Influencing Future Pricing:

• Speed of Generic Adoption: The rate at which physicians and patients switch to generic apixaban will directly impact branded pricing.
• Number of Generic Entrants: A larger number of generic manufacturers will intensify price competition.
• Payer Policies: Formularies and reimbursement policies from major payers will dictate market access and price sensitivity.
• Geographic Variations: Pricing will differ across regions due to local regulatory environments, healthcare systems, and economic conditions.
• Off-Label Use and New Indications: While less likely to influence broad pricing significantly post-patent expiry, any new, highly impactful indications could temporarily support premium pricing for the branded product if protected by specific use patents.

Key Takeaways

• Apixaban (Eliquis) is a leading anticoagulant with substantial current market value, projected to exceed \$45 billion by 2030, driven by increasing cardiovascular disease prevalence and its favorable clinical profile.
• The competitive landscape is intense, with rivaroxaban being the primary competitor. The primary market driver for future price changes is the impending and ongoing patent expiries.
• Patent expiries have led to the entry of generic apixaban in key markets starting in 2022-2023.
• Generic apixaban entry is projected to cause a significant price reduction of 40-60% in the average selling price within two years of broad availability. Branded Eliquis prices will decline accordingly.

Frequently Asked Questions

1. When did generic apixaban become available in the United States? Generic versions of apixaban began to be approved and available in the United States in late 2023.

2. What is the primary mechanism of action for apixaban? Apixaban is a direct factor Xa inhibitor, meaning it directly blocks the activity of the enzyme factor Xa, which is crucial in the blood clotting cascade.

3. How does apixaban's bleeding risk compare to warfarin? Clinical trials generally show apixaban to have a lower risk of major bleeding compared to warfarin, particularly in patients with non-valvular atrial fibrillation.

4. What are the main indications for apixaban? The primary indications for apixaban include reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

5. Will the original manufacturer of Eliquis continue to sell the branded product after generic entry? Yes, Bristol Myers Squibb and Pfizer are expected to continue marketing branded Eliquis. However, its market share and pricing will be significantly impacted by generic competition.

Citations

[1] Global Market Insights. (2023). Anticoagulants Market Size, Share & Industry Analysis, By Drug Class, By Indication, By Distribution Channel, By Region, Forecasts 2023-2030. [2] Grand View Research. (2023). Apixaban Market Size, Share & Trends Analysis Report By Indication (Non-valvular Atrial Fibrillation, DVT & PE), By Dosage, By Distribution Channel, By Region, And Segment Forecasts, 2024-2030. [3] Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., Burke, G. L., Cross, K. H., Kheyfets, V., Lopez, A. D., Mancia, G., Manolis, A. J., Mbakwem, A. C., Oganov, R. G., Rahman, F., Sliwa, K., Wanga, G. X., & Zhao, D. (2016). Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation, 133(21), 2053–2062. [4] Granger, C. B., Anand, S. S., Turpie, A. G., et al. (2011). Apixaban versus warfarin for the prevention of stroke and major bleeding in patients with atrial fibrillation. The New England Journal of Medicine, 365(11), 981–992. [5] IQVIA. (2022). The Global Use of Medicines: Outlook 2022.